Chronic Graft Versus Host Disease
Conditions
Brief summary
While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT. Corticosteroids (or steroids) have been the mainstay of treatment for chronic GVHD for many decades now. Increasingly, newer immunosuppressive and immunomodulating agents are being studied in adults and children affected by cGVHD. Ruxolitinib is one of these promising newer agents, which has been shown to be effective in the treatment of cGVHD in both children and adults. Currently, ruxolitinib is generally added to a patient's treatment regimen after (or with) a course of high dose steroids. The purpose of this study is to examine the effectiveness of upfront single agent ruxolitinib for cGVHD.
Interventions
DRUGRuxolitinib
Participants will receive ruxolitinib for 6 months.
Sponsors
Children's Hospital Medical Center, Cincinnati
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed moderate to severe chronic graft versus host disease (as defined by NIH cGVHD consensus criteria), requiring systemic treatment * Patient aged ≥12 year-old and ≤30 year-old * Patient able to take oral or enteral medication * No active, clinically significant uncontrolled infections * ALT ≤ 5x upper limit of normal (ULN) and total bilirubin ≤ 5xULN (unless presumed liver GVHD) * Platelet ≥ 20k and ANC ≥ 500. The use of transfusions or growth factors is permitted to maintain counts at these thresholds * No prior systemic treatment for chronic GVHD. Patients previously treated for acute GVHD are eligible, including those who received ruxolitinib for treatment of their aGVHD * Patients must be on ≤ physiologic dosing (i.e. hydrocortisone 8-12mg/m2/day) at enrollment * Patients with prior acute GVHD on \< 1 mg/kg steroids with new onset moderate-severe chronic GVHD may be considered for enrollment if they can taper steroids to reach physiological hydrocortisone in 1 month. If unable to do so these patients will come off study and be replaced
Exclusion criteria
* Mild cGVHD (as defined by NIH cGVHD consensus criteria11), that does not require systemic therapy * Acute or late acute GVHD without any evidence of chronic GVHD features * Patients who have received corticosteroids for ≥ 24 hours at 1 mg/kg/day of methylprednisolone or prednisone with the intent to treat cGVHD at time of enrollment * Corticosteroid dosing above physiologic dose hydrocortisone (i.e. \> 8-12mg/m2/day) at time of enrollment * Clinical evidence suggesting active malignancy (including PTLD and primary/secondary malignancy) * Clinical evidence of clinically significant active infection * Ongoing cytopenias which cannot be supported with routine supportive care (keeping hemoglobin over 7 g/dL and platelets \>20,000 and absolute neutrophil count over 500/uL) * Active lower gastrointestinal bleeding * Thrombosis within 6 months (including myocardial infarction, stroke, deep venous thrombosis, pulmonary embolism). IV infiltration will not be included as an example of thrombosis * Pregnant or lactating females; patients of childbearing age who are not able to comply with contraceptive recommendations * Other condition that PI feels would preclude the patient from complying with study activities * ESRD \[CLcr \< 15 mL/min\] not on dialysis * Overlap syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate | 6 months |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORPooja Khandelwal, MD
Children's Hospital Medical Center, Cincinnati
Outcome results
None listed